4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $38.00 by Analysts at Roth Capital

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price lowered by Roth Capital from $44.00 to $38.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also weighed in on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Tuesday, July 29th. The Goldman Sachs Group dropped their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday. Finally, Barclays dropped their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $30.40.

4D Molecular Therapeutics Trading Up 11.2%

NASDAQ:FDMT opened at $6.15 on Tuesday. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $17.41. The business’s 50-day moving average price is $4.50 and its two-hundred day moving average price is $4.09. The firm has a market capitalization of $284.93 million, a price-to-earnings ratio of -1.74 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 38.38%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. Sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth about $50,000. Velan Capital Investment Management LP bought a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $56,000. Virtus ETF Advisers LLC grew its stake in 4D Molecular Therapeutics by 173.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company’s stock valued at $58,000 after purchasing an additional 6,560 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in 4D Molecular Therapeutics in the second quarter valued at approximately $42,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in 4D Molecular Therapeutics in the first quarter valued at approximately $39,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.